Electrocore (NASDAQ:ECOR) and Medtronic (NYSE:MDT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.
This table compares Electrocore and Medtronic’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Electrocore and Medtronic’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Medtronic||$29.95 billion||4.00||$3.10 billion||$4.77||18.71|
Medtronic has higher revenue and earnings than Electrocore. Electrocore is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.
Medtronic pays an annual dividend of $2.00 per share and has a dividend yield of 2.2%. Electrocore does not pay a dividend. Medtronic pays out 41.9% of its earnings in the form of a dividend. Medtronic has increased its dividend for 41 consecutive years.
This is a summary of current ratings for Electrocore and Medtronic, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Electrocore currently has a consensus target price of $21.50, suggesting a potential upside of 281.88%. Medtronic has a consensus target price of $103.32, suggesting a potential upside of 15.79%. Given Electrocore’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Electrocore is more favorable than Medtronic.
Insider and Institutional Ownership
14.5% of Electrocore shares are held by institutional investors. Comparatively, 81.5% of Medtronic shares are held by institutional investors. 0.3% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Medtronic beats Electrocore on 13 of the 17 factors compared between the two stocks.
electroCore, LLC, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. It is developing gammaCore, a prescription-only vagus nerve stimulation therapy, for the acute treatment of pain associated with migraine and episodic cluster headache in adults. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation product; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Minimally Invasive Therapies Group segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, and gynecology products; hardware instruments and mesh fixation device; and gastrointestinal, inhalation therapy, and renal care solutions. The Restorative Therapies Group segment offers products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, colorectal surgeons, urogynecologists, interventional radiologists, and ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and therapy management software. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Electrocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electrocore and related companies with MarketBeat.com's FREE daily email newsletter.